Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07020923 · ClinicalTrials.gov registry record · Phase 2
Monthly Dosing of Atacicept in IgAN
A Phase 2 study of IgA Nephropathy (IgAN) and Berger Disease, sponsored by Vera Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT07020923: Recruiting Phase 2 study of IgA Nephropathy (IgAN) and Berger Disease, sponsored by Vera Therapeutics.
NCT07020923 is a Phase 2 study of IgA Nephropathy (IgAN) and Berger Disease that is actively recruiting participants, run by Vera Therapeutics. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07020923, a Phase 2 study of IgA Nephropathy (IgAN) and Berger Disease, is actively recruiting participants, sponsored by Vera Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
Primary Outcome
Gd-IgA1 levels through Week 24
Conditions Studied
Interventions
- DRUG Atacicept
Study Locations (1)
California
- Vera Therapeutics - Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-05-29 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT07020923 shows while recruiting
NCT07020923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 2 conditions, with IgA Nephropathy (IgAN) appearing as the primary indexed condition, and to 1 intervention - of which Atacicept is the first listed.
NCT07020923 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07020923 about?
NCT07020923 is a clinical study titled "Monthly Dosing of Atacicept in IgAN". This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
What is the current status of trial NCT07020923?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2025-05-29. Estimated completion is 2027-09.
What conditions does trial NCT07020923 study?
This clinical trial studies the following conditions: IgA Nephropathy (IgAN), Berger Disease.
What interventions are being tested in trial NCT07020923?
The interventions under investigation include: Atacicept (DRUG).
Who is sponsoring clinical trial NCT07020923?
This trial is sponsored by Vera Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07020923 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgA Nephropathy (IgAN)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07020923's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI